Asad Haider
Stock Analyst at Goldman Sachs
(2.85)
# 1,645
Out of 5,182 analysts
15
Total ratings
85.71%
Success rate
18.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $102.06 | +39.13% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $225.34 | +6.51% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $30.45 | +21.51% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $57.78 | -1.35% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $23.36 | -27.23% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $49.65 | -15.41% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $59.72 | -36.37% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $868.27 | +2.27% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $197.38 | -1.71% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $26.79 | -6.68% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $102.06
Upside: +39.13%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $225.34
Upside: +6.51%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $30.45
Upside: +21.51%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $57.78
Upside: -1.35%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $23.36
Upside: -27.23%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $49.65
Upside: -15.41%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $59.72
Upside: -36.37%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $868.27
Upside: +2.27%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $197.38
Upside: -1.71%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $26.79
Upside: -6.68%